A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using Investigational 1-mL Pre-filled Syringes and Investigational 2-mL Autoinjector in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Mirikizumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
- 19 Nov 2018 Planned End Date changed from 28 Feb 2019 to 24 Jan 2019.
- 19 Nov 2018 Planned primary completion date changed from 28 Feb 2019 to 24 Jan 2019.
- 19 Nov 2018 Status changed from recruiting to active, no longer recruiting.